Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Blood (2025) 146 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2025-1737

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2025-1842

Published: 2025

Journal Articles

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

Marco Ladetto, David Lavie, Tae Min Kim, Eva Gonzalez Barca, Ewa Paszkiewicz-Kozik, Stefan Hohaus, Caterina Patti, Jan Zaucha, Ömür Gökmen Sevindik, Yulia Volchek, Raul Cordoba, Guillermo Rodríguez Garcia, Sebastian Giebel, Benedetta Puccini, Tadeusz Robak, Siruo Wang, Puja Patel, Rushdia Yusuf, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 5516.

https://doi.org/10.1182/blood-2025-5516

Published: 2025

Journal Articles

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2025-4521

Published: 2025

Journal Articles

The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 6067.

https://doi.org/10.1182/blood-2025-6067

Published: 2025

Journal Articles

Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2025-4279

Published: 2025

Journal Articles

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 3620.

https://doi.org/10.1182/blood-2025-3620

Published: 2025

Journal Articles

Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP

Blood (2025) 146 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2025-6290

Published: 2025

Journal Articles

Minimal residual disease-guided venetoclax plus rituximab for patients with previously untreated chronic lymphocytic leukemia (VERITA PALG-CLL5): primary endpoint analysis of the prospective, multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 5675.

https://doi.org/10.1182/blood-2025-5675

Published: 2025

Journal Articles

Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocol

Blood (2025) 146 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2025-5134

Published: 2025

Journal Articles

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Blood (2025) 146 (Supplement 1): 344.

https://doi.org/10.1182/blood-2025-344

Published: 2025

Journal Articles

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Blood (2025) 146 (8): 1011–1029.

https://doi.org/10.1182/blood.2024027197

Published: 2025

Includes: Supplemental data

Journal Articles

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2024-205455

Published: 2024

Journal Articles

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 2193.

https://doi.org/10.1182/blood-2024-208242

Published: 2024

Journal Articles

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Blood (2024) 144 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2024-201076

Published: 2024

Journal Articles

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 112.

https://doi.org/10.1182/blood-2024-201946

Published: 2024

Journal Articles

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 578.

https://doi.org/10.1182/blood-2024-200271

Published: 2024

Journal Articles

The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)

Blood (2024) 144 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2024-203488

Published: 2024

Journal Articles

Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT

Eolia Brissot, Myriam Labopin, Didier Blaise, Cristina Castilla-Llorente, Annoek E. C. Broers, Nicolaus Kröger, Jakob R. Passweg, Andrew Bruce McDonald, Lucía López-Corral, Zinaida Peric, Sebastian Giebel, Arnon Nagler, Mohamad Mohty, Fabio Ciceri, Francesca Kinsella, Ludovic Gabellier

Blood (2024) 144 (Supplement 1): 508.

https://doi.org/10.1182/blood-2024-207681

Published: 2024

Journal Articles

Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

Sebastian Giebel, Anna Czyz, Iwona Hus, Lidia Gil, Krzysztof Giannopoulos, Joanna Romejko-Jarosinska, Maciej Majcherek, Agnieszka Szeremet, Anna Wache, Paulina Kwasnik, Wlodzimierz Mendrek, Wojciech Jurczak

Blood (2024) 144 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2024-209931

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the ALWP/EBMT

Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP

Minimal residual disease-guided venetoclax plus rituximab for patients with previously untreated chronic lymphocytic leukemia (VERITA PALG-CLL5): primary endpoint analysis of the prospective, multicenter, Phase 2 trial

Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocol

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)

Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT

Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only